Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.
| Revenue (TTM) | $581.85M |
| Gross Profit (TTM) | $399.45M |
| EBITDA | $80.14M |
| Operating Margin | 12.20% |
| Return on Equity | 25.70% |
| Return on Assets | 5.49% |
| Revenue/Share (TTM) | $8.65 |
| Book Value | $3.35 |
| Price-to-Book | 5.25 |
| Price-to-Sales (TTM) | 2.01 |
| EV/Revenue | 2.437 |
| EV/EBITDA | 13.67 |
| Quarterly Earnings Growth (YoY) | 327.30% |
| Quarterly Revenue Growth (YoY) | 3.80% |
| Shares Outstanding | $68.31M |
| Float | $34.30M |
| % Insiders | 11.65% |
| % Institutions | 82.05% |
Volatility is currently expanding
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Bioventus NASDAQ: BVS reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics and international operations.
Bioventus (BVS) came out with quarterly earnings of $0.22 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.21 per share a year ago.
DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 27, 2026.
Bioventus (BVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market opens on Wednesday, August 5, 2026.
Here is how Bioventus (BVS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
The consensus price target hints at a 28.9% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BVS and any ticker you trade — then tracks every position and per-strategy win rate.
